Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients
Syed S Mahmood,Peter A Riedell,Stephanie Feldman,Gina George,Stephen A Sansoterra,Thomas Althaus,Mahin Rehman,Elena Mead,Jennifer E Liu,Richard B Devereux,Jonathan W Weinsaft,Jiwon Kim,Lauren Balkan,Tarek Barbar,Katherine Lee Chuy,Bhisham Harchandani,Miguel-Angel Perales,Mark B Geyer,Jae H Park,M Lia Palomba,Roni Shouval,Ana A Tomas,Gunjan L Shah,Eric H Yang,Daria L Gaut,Michael V Rothberg,Evelyn M Horn,John P Leonard,Koen Van Besien,Matthew J Frigault,Zhengming Chen,Bhoomi Mehrotra,Tomas G Neilan,Richard M Steingart
DOI: https://doi.org/10.1093/eurheartj/ehad117
2023-06-09
Abstract:Aims: Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient's immune system to target cancer. There are sparse existing data characterizing death outcomes after CAR-T-related cardiotoxicity. This study examines the association between CAR-T-related severe cardiovascular events (SCE) and mortality. Methods and results: From a multi-centre registry of 202 patients receiving anti-CD19 CAR-T, covariates including standard baseline cardiovascular and cancer parameters and biomarkers were collected. Severe cardiovascular events were defined as a composite of heart failure, cardiogenic shock, or myocardial infarction. Thirty-three patients experienced SCE, and 108 patients died during a median follow-up of 297 (interquartile range 104-647) days. Those that did and did not die after CAR-T were similar in age, sex, and prior anthracycline use. Those who died had higher peak interleukin (IL)-6 and ferritin levels after CAR-T infusion, and those who experienced SCE had higher peak IL-6, C-reactive protein (CRP), ferritin, and troponin levels. The day-100 and 1-year Kaplan-Meier overall mortality estimates were 18% and 43%, respectively, while the non-relapse mortality (NRM) cumulative incidence rates were 3.5% and 6.7%, respectively. In a Cox model, SCE occurrence following CAR-T was independently associated with increased overall mortality risk [hazard ratio (HR) 2.8, 95% confidence interval (CI) 1.6-4.7] after adjusting for age, cancer type and burden, anthracycline use, cytokine release syndrome grade ≥ 2, pre-existing heart failure, hypertension, and African American ancestry; SCEs were independently associated with increased NRM (HR 3.5, 95% CI 1.4-8.8) after adjusting for cancer burden. Conclusion: Chimeric antigen receptor T-cell therapy recipients who experience SCE have higher overall mortality and NRM and higher peak levels of IL-6, CRP, ferritin, and troponin.